According to a recent note by analyst James Reddoch of Friedman, Billings, Ramsey, an injunction hearing related to the molecule is scheduled for Jan. 30.

FORBES: Magazine Article

But James Reddoch at Friedman, Billings, Ramsey has written notes to investors saying that Reclast is, in fact pretty good--and that its efficacy will be hard to beat.

FORBES: Amgen's Next Opponents

Fifth Third Bancorp gets the thumbs-down from Bradley Vander Ploeg at Raymond James and Gary Townsend at Friedman Billings Ramsey.

FORBES: When Picky Analysts Pick